Role of @entity16262 and its involving pathway in XXXX .

@entity1 @entity16262 @entity470 @entity996 @entity16719 @entity1721 @entity189 @entity7952 @entity418 @entity22030
BACKGROUND: @entity418 is a lethal disease and the optimal therapy remains unclear. Neoadjuvant chemotherapy provides an increased chance of survival; therefore, we attempted to identify potential molecular markers that might improve evaluations of individual responses to therapy. METHODS: We recruited 109 @entity1 with resectable @entity1721 . The @entity1 underwent radical esophagectomy and did not receive any other perioperative treatment. Expression of @entity16262 and molecules involved in its targeted pathways, @entity7952 , @entity22030 , @entity996 , @entity470 , @entity16719 and pAKT, was investigated immunohistochemically. RESULTS: Correlations were observed between @entity16262 and @entity996 expression; @entity16719 expression was significantly correlated with the degree of @entity189 differentiation (P = 0.01). Stage III @entity1 were found to have longer survival if they did not express @entity7952 than if they did (23 months vs. 11 months, P = 0.01). @entity1 with @entity16262 not expressing @entity996 were found to have longer survival times than those with @entity16262 who expressed @entity996 (18.8 months vs. 8.6 months, P = 0.021). Similarly, stage III @entity1 with @entity16262 but not expressing @entity7952 also survived longer than those expressing @entity7952 (23.5 months vs. 3.9 months, P < 0.001). CONCLUSIONS: A high expression of @entity7952 was significantly associated with poor survival in @entity1 with locally advanced @entity418 . Expression of a combination of molecules, rather than of individual molecules, was more predictive of disease prognosis. @entity16262 and molecules of its targeted pathways may be candidate proteins as markers of chemosensitivity in @entity418 @entity1 .
